Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD) (NETADHD)

Hallym University

Status and phase: Completed; Phase 4

Conditions: Methylphenidate; Attention Deficit Disorder With Hyperactivity; Pharmacogenetics

Treatments: Genetic: norepinephrine transporter polymorphism,

Study type: Interventional

Funder types: Other

Identifiers

NCT00757029

NETADHD

Details and patient eligibility

About

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

Enrollment: 150 estimated patients

Sex: All

Ages: 6 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ADHD
• Physically healthy

Exclusion criteria

• Neurological illness
• Concurrent additional psychiatric treatment
• < IQ 70
• Psychotic disorder
• Major mood disorder needed other psychiatric medication
• Significant suicidal ideation
• Pervasive developmental disorder

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

150 participants in 1 patient group

open label

Other group

Treatment:

Genetic: norepinephrine transporter polymorphism,